#AHA20 – Randomized trial: Among patients with recurrent pericarditis, Rilonacept was associated with lower risk of pericarditis recurrence than placebo

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Rilonacept Prevents Recurrent Pericarditis: RHAPSODY – TCTMD AND Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes stuDY – RHAPSODY – American College of Cardiology AND Trial shows drug effective in 96% of patients with recurrent pericarditis – Cleveland Clinic

Commentary on Twitter

Patients with recurrent pericarditis were treated with the interleukin-1 trap rilonacept. Those who had a response were randomly assigned to receive continued rilonacept or placebo. Rilonacept led to a significantly lower risk of pericarditis recurrence than placebo. #AHA20

— NEJM (@NEJM) November 17, 2020